ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS

Their core work

Chimie ParisTech is one of France's elite chemistry engineering schools, specializing in medicinal inorganic chemistry and metal-based therapeutic agents. Their core research develops ruthenium polypyridyl complexes for photodynamic therapy (PDT) — using light-activated metal compounds to selectively destroy cancer cells. They also contribute expertise in computational spectroscopy, physical chemistry of confined systems, and increasingly in nucleic acid-based therapies including CRISPR gene editing and bioinorganic materials for drug delivery.

What they specialise in

How they've shifted over time

In the early H2020 period (2015-2018), their work centered firmly on inorganic chemistry fundamentals: ruthenium metal complexes for photodynamic cancer therapy, physical chemistry of confined systems, and plant fibre composites. From 2020 onward, a clear pivot emerges toward biological applications of chemistry — nucleic acid therapies, CRISPR gene editing, DNA crystallography, and bioinorganic materials. This trajectory shows a group moving from designing therapeutic metal compounds toward integrating those capabilities with the molecular biology revolution in gene editing and immunotherapy.

They are bridging inorganic chemistry with genetic medicine — expect future work at the intersection of metal-based agents and nucleic acid therapeutics, a niche few chemistry schools occupy.

How they like to work

They operate as both project leaders and specialist contributors in roughly equal measure: 3 projects as coordinator, 3 as participant, and 3 as third party. Their coordinated projects are smaller, focused fellowships and grants (MSCA, ERC), suggesting they lead investigator-driven research rather than large industrial consortia. With 59 unique partners across 20 countries, they maintain a broad but research-oriented network — characteristic of a prestigious institution that attracts international talent through individual excellence programs.

They have collaborated with 59 unique partners across 20 countries, reflecting a wide European research network. Their connections span universities and research organizations rather than industrial partners, consistent with their ERC and MSCA funding profile.

What sets them apart

Chimie ParisTech occupies a rare niche at the intersection of inorganic chemistry and cancer medicine — specifically, designing light-activated metal compounds that kill tumour cells. Very few institutions in Europe combine this depth in ruthenium photochemistry with growing capability in nucleic acid therapies and gene editing tools. For consortium builders, they bring a chemistry school's rigorous synthetic and analytical capabilities to biomedical problems that most biology-focused partners cannot address from the materials side.

Highlights from their portfolio

• PhotoMedMet
  Their flagship: an ERC Consolidator Grant worth EUR 2M (2016-2022) on inert phototoxic Ru(II) complexes — the largest single grant and a mark of individual research excellence.
• NATURE-ETN
  Signals their strategic pivot: a training network on CRISPR, gene editing, and nucleic acid therapy that connects their chemistry roots to the frontiers of genetic medicine.
• OrganometRuPDT
  Builds directly on PhotoMedMet with cancer-cell-specific organometallic photosensitizers, showing sustained leadership in a focused therapeutic niche.